Vasopressin Formulation Stability via Acidic Buffering
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations of vasopressin suffer from poor long-term stability, leading to degradation issues that affect their efficacy in clinical applications.
Innovation Solution
A pharmaceutical composition comprising vasopressin or its pharmaceutically-acceptable salt in combination with a polymeric excipient, which reduces degradation by about 5-10% over a week at 60°C, when stored with a buffer at acidic pH.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current formulations of vasopressin are used, then the drug can be administered for clinical treatment, but the formulations suffer from poor long-term stability and degradation
Solution Approach 1:
The patent changes the pH parameter of the formulation to an acidic range (pH 2-5) to improve vasopressin stability. This parameter change reduces degradation by a factor of 5-10 fold compared to neutral pH formulations, directly addressing the stability problem while maintaining clinical efficacy
Solution Approach 2:
The patent creates a composite formulation system combining vasopressin with acidic buffers (such as acetate, citrate, or phosphate buffers) to achieve enhanced stability. This composite approach allows the formulation to maintain both therapeutic effectiveness and improved long-term stability
2Ease of operation
If vasopressin is stored at room temperature or refrigeration, then accessibility and ease of storage improve, but degradation still occurs over time
Solution Approach 1:
By changing the pH parameter to acidic conditions, the formulation achieves extended shelf life at room temperature (25°C) and refrigeration (5°C) without significant degradation. This allows the product to be stored and distributed more easily while maintaining stability for at least 12 months
Solution Approach 2:
The acidic buffer system acts as a protective cushion against degradation processes before they can significantly affect the vasopressin. This preemptive stabilization allows the formulation to withstand storage conditions without rapid degradation, extending shelf life while maintaining ease of storage
Data Source
AI summary
Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.